Recent News for HURA - TuHURA Biosciences, Inc.

Date Title
Sep 20 Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
Sep 18 Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
Sep 11 Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Sep 9 Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Aug 19 TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Jul 8 TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
Jul 1 Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Jun 18 Why Chegg Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Jun 3 TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
May 15 Kintara Therapeutics GAAP EPS of -$0.05
Back to the Main HURA Page...